Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GlaxoSmithKline

Sanofi (SNY) recombinant protein-based technology is being combined with Glaxo's (GSK) pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.

Sanofi/Glaxo to Supply 300M Coronavirus Vaccine Doses in EU

GlaxoSmithKline and Sanofi stock are rallying in early trading on Friday thanks to news they would supply the EU 300 million vaccine doses.
The post GlaxoSmithKline and Sanofi Stock Rally on EU Vaccine Deal appeared first on InvestorPlace.

GlaxoSmithKline and Sanofi Stock Rally on EU Vaccine Deal

Shares of Sanofi (NASDAQ: SNY) rose by 0.17% in the past three months. Before having a look at the importance of debt, let us look at how much debt Sanofi has.

Sanofi: Debt Insights

AstraZeneca

Biogen

Momenta Pharmaceuticals

Neoleukin Therapeutics Inc

Perrigo

Relmada Therapeutics Inc

Supernus Pharmaceuticals

Takeda Pharmaceutical

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Pharmaceutical Stocks for Q4 2020

Sanofi's (SNY) blockbuster drug, Dupixent gets Breakthrough Therapy designation from the FDA as potential treatment for eosinophilic esophagitis.

Sanofi's Dupixent Gets Breakthrough Status for New Indication

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)   

Sanofi : Information concerning the total number of voting rights and shares - July 2020

Is  (SNY) Outperforming Other Medical Stocks This Year?

Has Sanofi (SNY) Outpaced Other Medical Stocks This Year?

Advance Auto Parts

Big Lots

Janus Henderson Group

Rocky Brands

Universal Forest Products

A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.

7 Solid Low Price-to-Sales Picks With Room for Growth

AbbVie

Amgen

Gilead Sciences

Johnson & Johnson

Merck

Novartis

Pfizer

Roche Holding AG

As evidence grew this spring that the drug remdesivir was helping COVID-19 patients, some Wall Street investors bet on analysts’ estimates that its maker, Gilead Sciences Inc , could charge up to $10,000 for the treatment.

Big Pharma wages stealth war on drug price watchdog

CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Sanofi Genzyme today announced that new data from across the company's neurology portfolio will be presented at MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) - European Committee.

Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020

Moderna

Novavax

These healthcare companies have had plenty of help in building the manufacturing capacity needed to produce billions of vaccine doses.

6 Companies Racing to Mass-Produce a Coronavirus Vaccine in 2021

Bank of Nova Scotia

British American Tobacco

Cardinal Health

Canadian Natural Resources

Chevron

Diageo

Enbridge

Pembina Pipeline

People's United Financial

AT&T

These Kiplinger "Top Dividend Stocks From Around The World" (a.k.a. the most reliable dividends on earth) are perfect for the dogcatcher process.

A 91 Kiplinger 'Most Reliable Dividend Stocks On Earth' September Update

CEOs of nine of the leading coronavirus vaccine companies pledged to follow science and safety in their quest for a vaccine amid rising pressures from political leaders for a vaccine soon.
The post Covid Roundup: Coronavirus Vaccine Makers Pledge To Follow Science; Sanofi Eyes Price appeared first on Investor's Business Daily.

Covid Roundup: Coronavirus Vaccine Makers Pledge To Follow Science; Sanofi Eyes Price

BioNTech SE

Nine leading U.S. and European vaccine developers pledged to uphold the scientific standards that their experimental immunizations will be held against, amid a hurried global race to contain the pandemic.

Nine biopharma CEOs pledge to make safety the main focus in coronavirus vaccine development

Arrow Financial

Chubb

Con Ed

Essex Property Trust

Altria

National Fuel Gas

Sonoco Products

Sensient Technologies

TC Energy

Travelers

Volatility is back, with stocks selling off 4.3% in the last two days. Far larger declines might be coming soon, up to 10% according to some analysts, perhaps more.

15 High-Yield, Low Volatility Blue-Chips For The Ultimate Crash-Proof Retirement Portfolio

15 High-Yield, Low Volatility Blue-Chips For The Ultimate Sleep Well At Night Retirement Portfolio

"Political considerations should be put aside by Republicans and Democrats," the vaccine manufacturers' draft statement says, according to the Journal.

Drugmakers seek to reassure public on coronavirus vaccine safety with joint pledge

Sanofi's chief in France, Olivier Bogillot, said on Saturday that its future COVID-19 vaccine was likely to be priced below 10 euros per shot.

Sanofi France chief: future COVID-19 vaccine seen below 10 euros

A quick approval would be nice, but the drugmakers are sticking to their scientific principals.

Moderna, Pfizer, Johnson & Johnson, And Others To Make Pledge in Response to Coronavirus Vaccine Political Pressure

The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc.

Vaccine Hopes Rise Again: 4 Stocks to Watch

With competitors already in phase 3 development, the European drugmakers are just now starting a phase 1/2 clinical trial.

Better Late Than Never: Sanofi and GlaxoSmithKline Start Coronavirus Vaccine Clinical Trial Program

Sanofi (SNY) and Glaxo have a collaboration to develop an adjuvant vaccine against coronavirus.

Sanofi, Glaxo Start Clinical Study on Coronavirus Vaccine

Novavax and the team of Sanofi and GlaxoSmithKline separately reported trial advances with their Covid vaccine candidates, sending shares of NVAX and SNY rising in early trading Thursday.
The post Novavax Posts Good Covid Vaccine Data; Sanofi, GlaxoSmithKline Start First Human Tests appeared first on Investor's Business Daily.

Novavax Posts Good Covid Vaccine Data; Sanofi, GlaxoSmithKline Start First Human Tests

Shares of Sanofi SNY, +1.06% SAN, +0.97% gained 0.4% in premarket trading on Thursday after the drugmaker and GlaxoSmithKline GSK, +2.41% said their COVID-19 vaccine candidate has entered a Phase 1/2 clinical trial.

Sanofi, GSK's coronavirus vaccine candidate enters clinical trials

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline PLC (NYSE: GSK) on Thursday announced they had started the early-stage clincial trials for for their COVID-19 vaccine candidate the same day.

News for Sanofi Stock (SNY)